argenx SE Q3 2026 Earnings Recap

Argenx reported $1.7 billion in third-quarter product sales, up 54% year over year, while shares slipped 0.6% after the results. The reaction was roughly flat; the transcript highlights substantial pipeline activity and a December Phase III readout, but provides no new forward financial guidance in the portion provided.

Key Takeaways

• Product net sales were $1.7 billion, up 54% year over year and 13% quarter over quarter.
• U.S. product sales were $1.5 billion, up 16% quarter over quarter; net pricing was broadly consistent with prior quarters, and gross-to-net deductions were 22%, in line with expectations.
• Argenx expects the Phase III EMPASSION study readout in MMN in December. The trial compares empasiprubart with IVIg and tests whether it can deliver comparable efficacy with less treatment burden.
• The company plans to file an sBLA for VYVGART in IMNM by year-end and is moving toward an additional registrational study in dermatomyositis.
• Management expects five potential launches across the portfolio in 2027 and 10 molecules in clinical development by year-end.